Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 37Terminated 5Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Solitary Fibrous Tumor, Pleural 1Seminoma 1Mesothelioma, Malignant 1Carcinoma, Small Cell 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Interventional × ARQ 197 × Clear all
NCT02608411 2023-10-13

TIMES

Istituto Oncologico Veneto IRCCS

Phase 2 Terminated
5 enrolled

Carcinoma, Small Cell

NCT01055067 2021-04-06

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Daiichi Sankyo

Phase 2 Terminated
27 enrolled 6 charts

Seminoma

NCT01244191 2021-04-06

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Daiichi Sankyo

Phase 3 Terminated
1,048 enrolled 15 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01377376 2016-12-07

ATTENTION

Kyowa Kirin Co., Ltd.

Phase 3 Terminated
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01861301 2016-10-24

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

National Cancer Institute (NCI)

Phase 2 Terminated
18 enrolled 7 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡